Live Analyst Rating Changes 31643 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mark Massaro
BTIG

Mark Massaro

BTIG
Wall Street Analyst
★★★★☆
#663
on 13Foresight · ranked by our own returns
66%
Success Rate
+20.2%
Average Return
42 of 64 calls profitable · +52.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 66% of Mark Massaro's ratings turned a profit when each position was held for 1 year — averaging +20.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

91 Buy 20 Hold 2 Sell
Mark's Stock Coverage 37 ratings · 2026-09-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
DNA
Ginkgo Bioworks Holdings
 Sep 04, 2026 SELL Strong Sell
+5.1% avg upside
6 analysts
$5.00
26.02% Downside
 -0.0% ·
GH
Guardant Health
 Sep 01, 2026 BUY Strong Buy
+5.3% avg upside
32 analysts
$195.00
23.92% Upside
 -4.3% ·
MXCT
MaxCyte
 Aug 24, 2026 HOLD Strong Buy
+244.7% avg upside
5 analysts
 — -7.9% ·
MDXH
MDxHealth
 Aug 21, 2026 BUY Strong Buy
+753.2% avg upside
9 analysts
$2.00
183.78% Upside
 -9.0% ·
TEM
Tempus AI, Inc. Class A
 Aug 20, 2026 BUY Strong Buy
+15.2% avg upside
23 analysts
$80.00
35.51% Upside
 -11.5% ·
IMDX
Insight Molecular Diagnostics
 Aug 18, 2026 HOLD Buy
+28.0% avg upside
10 analysts
 — -3.5% ·
FRNM
Freenome Inc
 Aug 17, 2026 BUY Strong Buy
+25.2% avg upside
4 analysts
$17.00
18.29% Upside
 +25.5% ·
LUCD
Lucid Diagnostics
 Aug 17, 2026 BUY Strong Buy
+522.0% avg upside
8 analysts
$2.50
219.30% Upside
 -3.9% ·
CERS
Cerus
 Aug 14, 2026 BUY Strong Buy
+115.8% avg upside
10 analysts
$4.00
60.71% Upside
 -17.4% ·
TKNO
Alpha Teknova
 Aug 11, 2026 BUY Strong Buy
+89.6% avg upside
7 analysts
$8.00
19.24% Upside
 -1.7% ·
CAI
Caris Life Sciences, Inc.
 Aug 07, 2026 BUY Strong Buy
+14.3% avg upside
20 analysts
$33.00
35.48% Upside
 +7.8% ·
NTRA
Natera
 Aug 07, 2026 BUY Strong Buy
-5.1% avg upside
28 analysts
$320.00
2.79% Downside
 +2.5% ·
BLLN
BillionToOne, Inc. Class A
 Aug 06, 2026 BUY Strong Buy
+23.6% avg upside
10 analysts
$130.00
31.60% Upside
 +11.0% ·
CDNA
CareDx
 Aug 06, 2026 BUY Buy
-15.2% avg upside
18 analysts
$60.00
19.47% Upside
 +11.7% ·
SOPH
SOPHiA GENETICS
 Aug 05, 2026 BUY Strong Buy
+33.4% avg upside
8 analysts
$9.00
14.36% Upside
 +28.4% ·
XGN
Exagen
 Aug 05, 2026 BUY Strong Buy
+79.4% avg upside
11 analysts
$9.00
27.98% Upside
 +14.0% ·
WGS
GeneDx Holdings
 Aug 04, 2026 BUY Strong Buy
-5.4% avg upside
9 analysts
$90.00
5.55% Upside
 +18.4% ·
CSTL
Castle Biosciences
 Aug 03, 2026 BUY Strong Buy
+29.0% avg upside
9 analysts
$44.00
36.07% Upside
 +6.3% ·
ADPT
Adaptive Biotechnologies
 Jul 30, 2026 BUY Strong Buy
-1.7% avg upside
15 analysts
$25.00
3.28% Upside
 +0.1% ·
NEO
NeoGenomics
 Jul 28, 2026 HOLD Buy
+2.7% avg upside
18 analysts
 — +29.2% ·
PSNL
Personalis
 Jul 20, 2026 BUY Strong Buy
-7.2% avg upside
11 analysts
$16.25
0.21% Upside
 +22.9% ·
ZTS
Zoetis
 Feb 26, 2026 BUY Buy
+62.8% avg upside
23 analysts
$160.00
119.18% Upside
 -43.1% ·
IDXX
Idexx Laboratories
 Feb 03, 2026 BUY Buy
+43.4% avg upside
17 analysts
$800.00
58.57% Upside
 -15.4% ·
BNGO
BioNano Genomics
 Aug 22, 2025 HOLD Buy
+674.9% avg upside
9 analysts
 — -70.0% ·
RNLXY
Renalytix
 May 20, 2024 BUY Strong Buy
+156.0% avg upside
5 analysts
$2.00
52.46% Downside
 · ·
HLTHQ
Cue Health
 Mar 21, 2024 HOLD Hold
2 analysts
 — · ·
TTOO
T2 Biosystems
 Sep 22, 2023 HOLD Buy
+710525.0% avg upside
10 analysts
 — · ·
HTGMQ
HTG Molecular Diagnostics
 Dec 06, 2019 HOLD Strong Buy
+733333233.4% avg upside
6 analysts
 — · ·
QDEL
QuidelOrtho
 Nov 17, 2019 BUY Buy
+233.3% avg upside
13 analysts
$75.00
536.63% Upside
 +201.7% ·
OSUR
Orasure Technologies
 Nov 10, 2019 HOLD Buy
+161.7% avg upside
11 analysts
$8.00
146.19% Upside
 +54.8% ·
QTRX
Quanterix
 Nov 06, 2019 BUY Buy
+633.1% avg upside
8 analysts
$35.00
1267.22% Upside
 +157.7% ·
LH
Labcorp Holdings
 Oct 24, 2019 HOLD Strong Buy
-13.1% avg upside
37 analysts
$170.00
45.45% Downside
 +26.1% ·
ILMN
Illumina
 Oct 24, 2019 HOLD Buy
-12.8% avg upside
31 analysts
$310.00
50.16% Upside
 +2.5% ·
DGX
Quest Diagnostics
 Oct 22, 2019 BUY Buy
-21.7% avg upside
34 analysts
$113.00
51.82% Downside
 +28.2% ·
AWHL
Aspira Women's Health
 May 23, 2018 HOLD Buy
+1694.0% avg upside
6 analysts
$1.00
232.21% Upside
 · ·
RIOT
Riot Platforms
 Feb 09, 2016 HOLD Strong Buy
+43.1% avg upside
30 analysts
$4.00
81.27% Downside
 · ·
BDX
Becton Dickinson
 May 07, 2015 HOLD Buy
+10.8% avg upside
25 analysts
$145.00
18.50% Downside
 +17.5% ·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mark Massaro — Frequently Asked Questions
How accurate are Mark Massaro's stock ratings?
Based on the calls 13Foresight could measure, about 66% of Mark's ratings were profitable over a one-year hold, with an average return of +20.2% per rating, or +52.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mark ranked on 13Foresight?
Mark Massaro is currently ranked #663 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mark cover?
Mark most recently has ratings on DNA, GH, MXCT, MDXH, TEM, IMDX, FRNM, LUCD, CERS, TKNO, CAI, NTRA and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.